End-of-day quote
Other stock markets
|
||
- | - |
2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Sales 2024 * | 75.5B 55.87M 0 4.4B | Sales 2025 * | 156B 115M 0 9.1B | Capitalization | 10,047B 7.43B 0 586B |
---|---|---|---|---|---|
Net income 2024 * | 13B 9.62M - 758M | Net income 2025 * | 62B 45.88M - 3.62B | EV / Sales 2024 * | 133 x |
Net cash position 2024 * | 10B 7.4M 0 583M | Net cash position 2025 * | 63B 46.62M 0 3.67B | EV / Sales 2025 * | 64 x |
P/E ratio 2024 * |
738
x | P/E ratio 2025 * |
157
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.48% |
Managers | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 12/05/08 |
Sang-Woo Kang
DFI | Director of Finance/CFO | 58 | 31/05/20 |
Gyu-Wan Kim
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Sun-Jae Park
CEO | Chief Executive Officer | 69 | 12/05/08 |
Jong-In Choi
BRD | Director/Board Member | 59 | 28/03/21 |
In-Young Go
BRD | Director/Board Member | 68 | 28/03/21 |
1st Jan change | Capi. | |
---|---|---|
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-10.90% | 33.49B | |
-19.56% | 14.62B | |
-9.06% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |